In our office, we performed simple tests to document the cohesiveness and resistance to traction force of both gels. In two different laboratories, the rheological properties of both gels were measured. We used comparative data of the gel without lidocaine collected from over 6 years. We also observed the gels' behavior when injected into the superficial and mid-reticular dermis, comparing their distribution using both ultrasonography and histology.
| INTRODUC TI ON
process. We, along with other teams, have published papers on this gel. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In 2011, the Belotero ® Balance CPM ® HA gel, without lidocaine, was approved by the USA Food and Drug Administration (FDA). In 2014, lidocaine was then added to the gel, and we have since performed several tests comparing gels with and without lidocaine. 12 At present, CPM ® gel with lidocaine is still awaiting FDA approval.
In this paper, we report the different tests we conducted on both gel types, in addition to some rheological data, along with our personal clinical impressions from treating more than 1200 patients.
| MATERIAL S AND ME THODS
Herein, we solely discuss the CPM ® Belotero® Balance HA gel, with and without lidocaine. The starting point of these gels is the dynamic cross-linking process on which the CPM ® technology is based.
| Rheology
Wherever possible, the same devices were used in 2006 and 2012.
All tests were performed in a private laboratory so as to obtain as reproducible results as possible for CPM ® HA gel without lidocaine.
Our tests were designed to assess whether there were any gel modifications occurring over time that could explain pop-off incidents, namely the dislocation from the body of the syringe of the syringe hub with the needle attached to it.
In 2006, we measured the "Balance ® " gel's pH using the HI8424 portable pH meter-HANNA instruments with a specific electrode for gels (FC200B), with measurements taken twice on the syringes at Measurements were taken using rough plane-plane geometry of 25 mm diameter. The temperature was regulated at 25° by a Peltier effect-induced plane. Each test was conducted at least twice on each sample to assess reproducibility.
| Visual, microscopic, and ultrasound observations
On several occasions, we analyzed the CPM ® gel with and without lidocaine without any preparation at either our clinic or the Viollier Laboratory in Geneva (Switzerland), following coloration with toluidine blue and bi-distilled water rinse. 13 At our clinic, the following devices and substances were used: Figure 1 ).
14,15
| Histology
Histological analyses were performed at the Viollier laboratory in Geneva, Switzerland. [14] [15] [16] For our comparatives studies, biopsies of the papules created in the subjects' gluteal region were taken using a 4 mm round punch under local anesthesia with 1% lidocaine without epinephrine. Following extraction, the samples were set in formalin, then sent to the Viollier laboratory for preparation, staining, and microscopic analysis. After preparation, the samples were colored with specific stains (colloidal iron, Alcian blue, hematoxylin and eosin) and then examined using a Zeiss ® Axiokop 40 microscope.
| RE SULTS

| Rheology
The pH and osmolarity results of the tests performed in both 2006
and 2012 have been summarized in Table 1 . Given that similar measurements were made, CPM ® gels were shown to exhibit great stability, irrespective of the batch tested or manufacturing dates.
Regarding rheology, in both 2006 and 2012, the measurements showed very similar values for G′, G″, and tan delta, all at 1 Hz frequency ( Table 2 The new strain sweep data revealed that adding lidocaine might modify the CPM ® gel's viscoelastic properties. After adding lidocaine, CPM ® gel was thus not as easy to inject, while being able to resist more stress when distorted. This may cause longer-lasting results for CPM ® gel with lidocaine than without lidocaine.
| Visual, microscopic, and ultrasound observations
In The cohesiveness of this gel, as well as its specificity, that is, monophasic cohesive and polydensified, was confirmed by the studies of Pr H. Sundaram, Flynn et al in 2015. 10, 11 At the Viollier laboratory, CPM ® gel with lidocaine, when spread, exhibited medium elasticity and relatively adhesive, cohesive behavior. The gel spread homogeneously, presenting no particles within.
It adhered excellently to glass slides. There was no gel dispersion during rinsing with 2 × 1 mL of bi-distilled water, while its adherence to the glass slide remained excellent. Under the microscope, CPM ® gel with lidocaine closely resembled that without. These results Several times, we noticed air bubbles appearing upon injection of the gel with lidocaine, despite pushing out air from the needle before the injection itself, as is systematically done ( Figure 5 ).
During the injection into the mid-reticular dermis, we quite often observed that CPM ® gel with lidocaine leaked slightly into the subcutaneous fat (hypodermis). The possible origin of this leak will be discussed later (Figure 4 ).
| Histology
| Injection into the superficial reticular dermis
For CPM ® without lidocaine on Day 0, all the biopsies we analyzed, as along with those reported by Rheinmuller et al in their
paper comparing three FDA-approved HA gels, 9, 10 prove that CPM ® gels achieve harmonious distribution across all the dermis layers. 3 For CPM ® without lidocaine on Days 8, 15, 114, and up to Day 365, CPM ® gel displayed a long-lasting distribution across all dermis layers, regardless of when the biopsy was performed. We observed no inflammatory reactions, even at histological follow-up 1 year later ( Figure 6 ).
For CPM ® with lidocaine on Day 0, the biopsies exhibited the same distribution as those without lidocaine ( Figure 6 ).
For CPM ® with lidocaine on Day 45, the biopsies had a similar aspect to those involving CPM ® gel without lidocaine. However, on Day 45, there was a very mild lymphocyte inflammatory reaction in the superficial and mid-dermis. This may thus confirm the gel leak observed in ultrasound in the hypodermis ( Figure 5 ). The tests conducted at Rheonova appeared to confirm our clinical impressions. 
| Injection into the mid-reticular dermis
F I G U R E 7 CPM ® Belotero ® Balance.
| D ISCUSS I ON
For 12 years, we have injected over 1200 patients with the CPM ® HA gel, both with and without lidocaine. When injected as a papula into the superficial reticular dermis under ultrasound guidance using the blanching technique, both gels produced the same perfect dermal bio-integration on imaging. The gel appeared isoechogenous compared to the non-injected surrounding dermis.
The papula was homogenous with no hypo-or hyper-echogenous areas within and no cone shadows. The CPM ® gel thus had no particles inside its matrix. During injection into the mid-reticular dermis, Belotero ® Balance CPM ® gel, with or without lidocaine, caused a mild leak into the hypodermis. This may be due to the fact that
Balance CPM ® presents a higher viscosity, especially with added lidocaine, and consequently slightly stronger resistance to injection. The gel leak in the hypodermis may also be due to following reasons: too high pressure on the plunger; too rapid expulsion of the gel; subjects being older than those in our previous studies (mean: 5-8 years older), potentially presenting more dermatoporosis in their dermis, 16 and therefore less resistance to pressure; and the dermis probably naturally presents a variable resistance according to the depth of injection. The fibers may be denser and more resistant in the surface, less so in the mid-dermis, and more relaxed in the deep dermis.
On observing this gel leak, we believe we have proof that, due to this gel's specific cross-linking process, it must be injected into the superficial reticular dermis, not in the mid-reticular layer, and is in fact specifically designed for this purpose, as are the other competing gels with the same treatment indications.
When injected into the superficial reticular dermis, histology
showed that CPM ® gel with or without lidocaine diffused harmoniously across all levels of the dermis. There was no inflammatory reaction, even 365 days following injection. There was also a perfect correlation between the ultrasound and histological images.
Given we occasionally observed a mild leak of the CPM ® gel in the hypodermis during injection into the mid-reticular dermis, we believe this represents proof that this specific gel, due to its patented cross-linking process, is perfectly adapted for injections in the superficial reticular dermis. It might be better, therefore, to avoid any deeper injections. The question that remains, though, for both this HA gel and all others on the market is: How is it possible that when injected into the mid-or deep reticular dermis, 19 or even often into the hypodermis, the gel still presents long-lasting correction of wrinkles or folds?
The We had the impression that the introduction of lidocaine into the gel increased the gel's viscosity, necessitating excessive force to be applied to the plunger during injection. We were deeply concerned by several cases of visible or palpable cords of gel during our first trials with the CPM ® gel with added lidocaine. Our practical experiments have definitely corroborated the rheological data most recently provided by Rheonova.
We were able to correct this problem by slightly modifying the angle of penetration of the needle bevel into the superficial reticular dermis. We now recommend an angle of 11° to 14° maximum in place of 9° to 12°. On the other hand, only the needle bevel has to be implanted, that is only 1 mm.
In this way, we are able to know exactly the depth at which we are injecting the gel, following the mathematical formula: "sinus angle of penetration multiplied by the implanted part of the needle (in cm) gives the injection depth (in mm)."
We also recommend that patients massage the injected area "intensively," three times a day if possible, during several days to 2-3 weeks, which was not recommended with the CPM ® gel of 10 years ago. This enables us to check if the gel with lidocaine
